Hypodiploidy is a major prognostic factor in multiple myeloma
…, C Brigaudeau, D Leroux, C Fruchart - Blood, The Journal …, 2001 - ashpublications.org
Conventional karyotypes performed before any treatment in 208 patients with multiple
myeloma were reviewed by the Groupe Français de Cytogénétique Hématologique. A total of …
myeloma were reviewed by the Groupe Français de Cytogénétique Hématologique. A total of …
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open …
…, H Ghesquières, F Jardin, S Bologna, C Fruchart… - The Lancet, 2011 - thelancet.com
Background The outcome of diffuse large B-cell lymphoma has been substantially improved
by the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy regimens. …
by the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy regimens. …
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 …
…, S Bologna, O Fitoussi, G Lepeu, C Fruchart… - The Lancet …, 2011 - thelancet.com
Background Diffuse large B-cell lymphoma is a common cancer in elderly patients. Although
treatment has been standardised in younger patients, no prospective study has been done …
treatment has been standardised in younger patients, no prospective study has been done …
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised …
…, H Ghesquières, M Hacini, C Fruchart… - The lancet …, 2013 - thelancet.com
Background Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin,
vincristine, and prednisone (R-CHOP) has become the standard of care for elderly patients with …
vincristine, and prednisone (R-CHOP) has become the standard of care for elderly patients with …
[HTML][HTML] Rituximab plus lenalidomide in advanced untreated follicular lymphoma
…, H Tilly, ML Palomba, C Fruchart… - … England Journal of …, 2018 - Mass Medical Soc
Background Rituximab plus chemotherapy has been shown to be effective in patients with
advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will …
advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will …
[PDF][PDF] Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide …
…, P Moreau, B Pegourie, D Caillot, C Fruchart… - J Clin …, 2014 - researchgate.net
Purpose The three-drug combination of lenalidomide, bortezomib, and dexamethasone (RVD)
has shown significant efficacy in multiple myeloma (MM). The Intergroupe Francophone …
has shown significant efficacy in multiple myeloma (MM). The Intergroupe Francophone …
LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients
…, B Lenormand, A Rossi, F Pezzella, C Fruchart… - 1994 - ashpublications.org
We have recently shown that an evolutionary conserved gene LAZ3, encoding a zinc finger
protein, is disrupted and overexpressed in some B-cell lymphomas (mainly with a large cell …
protein, is disrupted and overexpressed in some B-cell lymphomas (mainly with a large cell …
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study …
…, C Danho, D Caillot, C Hulin, C Fruchart… - Blood, The Journal …, 2010 - ashpublications.org
Autologous stem cell transplantation (ASCT) is recommended for younger patients with
newly diagnosed multiple myeloma. Achieving complete response (CR) or at least very good …
newly diagnosed multiple myeloma. Achieving complete response (CR) or at least very good …
[PDF][PDF] Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus …
…, RO Casasnovas, C Fruchart… - Journal of Clinical …, 2017 - researchgate.net
Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is
rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-…
rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-…
[PDF][PDF] Interim [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy …
…, J Dupuis, E Itti, F Jardin, C Fruchart… - Journal of clinical …, 2012 - researchgate.net
Purpose The prognostic value of [18F] fluorodeoxyglucose–positron emission tomography (PET),
interpreted according to visual criteria, is a matter of debate for diffuse large B-cell …
interpreted according to visual criteria, is a matter of debate for diffuse large B-cell …